Acurx Pharmaceuticals Inc. (ACXP)
ACXP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ACXP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001736243 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These matters raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $9.7M cash; operating cash flow -$1.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 6,058,135 (2026-11-12); 2,085,363 a year earlier; 13,767,977 three years earlier. 3y figure adjusted for split (1-for-20 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2025-08-05 | Source 2025-08-05 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-16 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CohnReznick LLP, Parsippany, New Jersey, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$2.6M | -$2.5M | $9.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$2.3M | -$1.7M | $10.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$1.7M | -$1.4M | $9.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$1.6M | -$1.2M | $7.6M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | Not filed | -$2.0M | -$1.9M | $5.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$2.2M | -$1.7M | $6.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$2.1M | -$2.1M | $4.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$2.8M | -$2.3M | $3.7M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-17 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-09-01 |
Source: SEC EDGAR submissions feed, 247 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.4% |
| 1 month | -20.0% |
| 3 months | -35.1% |
| Year to date | -61.4% |
| 1 year | -79.7% |
| From 52-week high | -85.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALZN | Alzamend Neuro Inc. | $1.18 | -4.84% | $5.7M |
| BLRX | BioLineRx Ltd. | $1.15 | -12.61% | $5.7M |
| APRE | Aprea Therapeutics Inc. | $0.4063 | -2.38% | $5.8M |
| LTRN | Lantern Pharma Inc. | $0.3890 | -10.18% | $5.8M |
| FBLG | FibroBiologics Inc. | $0.9034 | -2.00% | $6.1M |
| JAGX | Jaguar Health Inc. | $0.3864 | -7.74% | $5.2M |
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
| CVKD | Cadrenal Therapeutics Inc. | $1.40 | -7.28% | $5.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier